EGFR and neoplasm: Our study reveals that the EGFR-TKI-treatment-related oncogenic pathway changes contributing to EGFR-TKI resistance in EGFR-mutant NSCLC are paradoxically attributed to the targeting of tumor cells by an activated immune system.